Effects on growth hormone secretion following intravenous and subcutaneous injections of growth hormone-releasing factor (hGRF-44 NH2): comparison of immunoreactive plasma GRF levels. 1985

G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson

The effects of subcutaneous administration of three doses of human growth hormone-releasing factor (hGRF-44 NH2 or hGRF) at doses of 100, 300 and 600 micrograms were studied in six normal young men. GH responses obtained with 100 and 300 micrograms were negligible. In contrast, the 600 micrograms dose gave a profile of response comparable in timing and magnitude to that obtained with i.v. hGRF at maximal effect doses (20, 80, 100 micrograms). Plasma immunoreactive hGRF levels (IR-hGRF) were compared after s.c. and i.v. hGRF. Mean maximal plasma concentrations were comparable with s.c. 600 micrograms and i.v. 20 micrograms. Peaks occurred earlier with i.v. hGRF (5 min as opposed to 15 min): however, return to undetectable values was obtained between 90 and 120 min after s.c. or i.v. injections. These data suggest a great loss of the peptide between the subcutaneous space and blood, without delayed absorption. High variability in plasma IR-hGRF concentrations between the subjects after the same s.c. doses was observed.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012636 Secretory Rate The amount of a substance secreted by cells or by a specific organ or organism over a given period of time; usually applies to those substances which are formed by glandular tissues and are released by them into biological fluids, e.g., secretory rate of corticosteroids by the adrenal cortex, secretory rate of gastric acid by the gastric mucosa. Rate, Secretory,Rates, Secretory,Secretory Rates
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin
D013007 Growth Hormone-Releasing Hormone A peptide of 44 amino acids in most species that stimulates the release and synthesis of GROWTH HORMONE. GHRF (or GRF) is synthesized by neurons in the ARCUATE NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, GHRF stimulates GH release by the SOMATOTROPHS in the PITUITARY GLAND. Growth Hormone-Releasing Factor,Somatocrinin,Somatotropin-Releasing Factor 44,Somatotropin-Releasing Hormone,GHRH 1-44,GRF 1-44,Growth Hormone-Releasing Factor 44,Human Pancreatic Growth Hormone-Releasing Factor,Somatoliberin,hpGRF 44,Growth Hormone Releasing Factor,Growth Hormone Releasing Factor 44,Growth Hormone Releasing Hormone,Somatotropin Releasing Factor 44,Somatotropin Releasing Hormone

Related Publications

G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
June 1985, Molecular and cellular endocrinology,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
December 1985, The Journal of endocrinology,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
June 1987, Hybridoma,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
March 1984, Chemical & pharmaceutical bulletin,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
August 1983, Biochemical and biophysical research communications,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
January 1987, European journal of clinical pharmacology,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
April 1986, Clinical endocrinology,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
June 1971, Endocrinology,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
June 1985, Journal of endocrinological investigation,
G Sassolas, and S Biot-Laporte, and R Cohen, and A Elm Charfi, and S Ferry, and F Borson
November 1984, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!